Oura to acquire AI-native primary care startup Counsel Health for $625M

Oura has announced a $625 million acquisition of Counsel Health, an AI primary care service that pairs a chat-based medical AI with licensed physicians. Counsel's CEO, Muthu Alagappan, becomes Oura's chief clinical AI officer and about 70 staff join. Counsel will keep serving its enterprise partners. The article says the deal is expected to close before the end of 2027, which is an unusually long window and worth checking against the original announcement. Oura also reported Q3 revenue of $533M (up 153% year on year) and roughly $1.75B of fiscal 2026 revenue (up 92%). The extraction lists a press release as the source but gives no link to it.

This moves Oura from tracking health data towards delivering care, such as prescriptions, lab results, chronic care and referrals. That puts it in a more regulated space and gives it a revenue line beyond hardware, which matters for competitors like RingConn and Ultrahuman that mostly sell rings. For existing users the immediate change looks small, because Counsel has been inside the Oura app since June. The real tests are whether Oura can run clinical services safely at scale and whether people will pay for care through a wearable brand. Investors get a clearer picture of the strategy after the postponed IPO, but not proof that it works.

Phrases like "AI-native primary care" and "actionable care" describe ambition, not results. No outcome data, patient numbers, pricing or safety record for Counsel is cited. The strong revenue growth figures are Oura's own and sit alongside the deal without showing that Counsel contributes anything yet. The framing of the deal as a way to keep up with smart ring rivals is the article's interpretation, not something the facts establish.

1. 01Closing details: the actual completion date, any regulatory review, and whether the end of 2027 timeline holds or the article has it wrong.
2. 02Counsel usage and economics after the deal: number of Oura members using it, whether it becomes a paid tier or bundled feature, and how much revenue it adds in the next two to three quarterly reports.
3. 03Clinical and regulatory scrutiny: any state medical board, FDA or privacy actions, and how Oura handles use of health data from the ring in care decisions, plus whether the IPO is rescheduled.